Would you change systemic therapy in a patient with SCLC with stable systemic disease but CNS progression?  

This particular patient previously progressed on platinum and is currently on lurbinectidin for >18 months.  She had CR on PET.  Now presents with a third CNS progression (previous CNS treatment with SRS, then WBRT, plan for SRS with current lesions).  Should I change lurbinectedin in if systemic disease well controlled?  Or I consider changing to an agent with potentially better CNS penetration?